The urokinase plasminogen activator system in cancer: A putative therapeutic target?

Drug News and Perspectives

Volumn 21, Issue 2, 2008, Pages 107-116

  Killeen, S D ^a   Hennessey, A ^a   El Hassan, Y ^a   Waldron, B ^a  

^a Kerry General Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMIDINOPHYNELALANINE DERIVATIVE; ADENOVIRUS VECTOR; AMIDINE; ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE; CAVEOLIN; COMPLEMENTARY RNA; G PROTEIN COUPLED RECEPTOR; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN G; INTEGRIN; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PRODRUG; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; ULINASTATIN; UROKINASE; WX UK1; WXC 340;

ANTISENSE THERAPY; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; DRUG MECHANISM; GENE FUNCTION; GLIOMA; HUMAN; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 43049130010     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.2.1188197     Document Type: Review

References (151)

1. Appella, E. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987, 262(10): 4437-40.
2. Pollanen, J., Stephens, R., Salonen, E.M. and Vaheri, A. Proteolytic mechanisms operating at the surface of invasive cells. Adv Exp Med Biol 1988, 233: 187-99.
3. Pollanen, J., Vaheri, A., Tapiovaara, H. et al. Prourokinase activation on the surface of human rhabdomyosarcoma cells: Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class-2 plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1990, 87(6): 2230-4.
4. Vassalli, J.D., Baccino, D. and Belin, D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985, 100(1): 86-92.
5. Roldan, A.L., Cubellis, M.V., Masucci, M.T. et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990, 9(2): 467-74.
6. Behrendt, N., Roenne, E. and Danø, K. Domain interplay in the urokinase receptor-requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996, 271(37): 22885-94.
7. Ploug, M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 1998, 37(47): 16494-505.
8. Høyer-Hansen, G., Behrendt, N., Ploug, M., Danø, K., Waltz, D.A. and Chapman. H.A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994, 269(20): 14746-50.
9. Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A. and Preissner, K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996, 224(2): 344-53.
10. Collen, D. On the regulation of fibrinolysis. Thromb Haemost 1980, 43: 77-89.
11. Espana, F., Estelles, A., Fernandez, P.J., Gilabret, J., Sanchez-Cheuz, J. and Griffin, J.H. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thromb Haemost 1993, 70(6): 989-94.
12. Hess, S., Kanse, S.M., Kost, C. and Preissner, K.T. The versatility of adhesion receptor ligands in haemostasis: Morphoregulatory functions of vitronectin. Thromb Haemost 1995, 74(1): 258-65.
13. Sprengers, E.D. and Kluft, C. Plasminogen activator inhibitors. Blood 1987, 69(2): 381-7.
14. Declerck, P.J., De Mol, M., Alessi, M.C. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988, 263(30): 15454-61.
15. Cubellis, M.V., Wun, T.C. and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990, 9(4): 1079-85.
16. Andreasen, P.A., Kjoller, L., Christensen, L. and Duffy, M.J. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997, 72(1): 1-22.
17. Blasi, F. and Carmeliet, P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12): 932-43.
18. Sidenius, N. and Blasi, F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22(2-3): 205-22.
19. Wei, Y. et al. Regulation of integrin function by the urokinase receptor. Science 1996, 273(5281): 1551-5.
20. Yebra, M. et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 1996, 271(46): 29393-9.
21. Degryse, B., Orlando, S., Resnati, M., Rabbani, S.A. and Blasi, F. Urokinase/urokinase receptor and vitronectin/avb3 integrin induce Chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 2001, 20(16): 2032-43.
22. May, A. E. et al. Urokinase receptor (CD87) regulates leukocyte recruitment via beta2 integrins in vivo. J Exp Med 1998, 188(6): 1029-37.
23. Waltz, D.A. et al. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol 2000, 22(3): 316-22.
24. Giancotti, F.G. and Ruoslahti, E. Integrin signaling. Science 1999, 285(5430): 1028-32.
25. Resnati, M. et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996, 15(7): 1572-82.
26. Fazioli, F. et al. The urokinase-sensitive region of the urokinase receptor is responsible for its potent chemotactic activity. EMBO J 1997, 16(24): 7279-86.
27. Degryse, B. et al. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis, and cytoskeleton reorganization in rat smooth muscle cells via the urokinase receptor. Blood 1999, 94(2): 649-62.
28. Nguyen, D.H. et al. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000, 275(25): 19382-8.
29. Resnati, M. et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002, 99(3): 1359-64.
30. Wei, Y., Yang, X., Liu, Q., Wilkins, J.A. and Chapman, H.A. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999, 144(6): 1285-94.
31. Nguyen, D.H., Hussaini, I.M. and Gonias, S.L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998, 273(14): 8502-7.
32. Mahabeleshwar, G.H., Das, R. and Kundu G.C. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem 2004, 279(11): 9733-42.
33. Konakova, M., Hucho, F. and Schleuning, W.D. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem 1998, 253(2): 421-9.
34. Trigwell, S., Wood, L. and Jones, P. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem Biophys Res Commun 2000, 278(2): 440-6.
35. Tang, H., Kerins, D.M., Hao, Q., Inagami, T. and Vaughan, D.E. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 1998, 273(29): 18268-72.
36. Dumler, I., Weis, A., Mayboroda, O.A. et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998, 273(1): 315-21.
37. Waltz, D.A. and Chapman, H.A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994, 269(20): 14746-50.
38. Sidenius, N. and Blasi, F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000, 470(1): 40-6.
39. Stepanova, V. et al. Urokinase-dependent human vascular smooth muscle cells adhesion requires selective vitronectin phorphorylation by ecto-protein kinase CK2. J Biol Chem 2000, 277(12): 10265-72.
40. Nusrat, A.R. and Chapman, H.A. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991, 87(3): 1091-7.
41. Simon, D.I. et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996, 88(8): 3185-94.
42. Ma, Z., Webb, D.J., Jo, M. and Gonias, S.L. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001, 114(Pt. 18): 3387-96.
43. Rabbani, S.A. et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992, 267(20): 14151-6.
44. Kirchheimer, J.C., Wojta, J., Christ, G., Hienert, G. and Binder, B.R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987, 1(2): 125-8.
45. Yu, W., Kim, J. and Ossowski, L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997, 137(3): 767-77.
46. Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K. and Ossowski, L. Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38 (MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12(4): 863-79.
47. Aguirre Ghiso, J.A., Kovalski, K. and Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999, 147(1): 89-104.
48. Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L.R., Ploug, M., Rømer, J. Plasminogen activation and cancer. Thromb Haemost 2005, 93(4): 676-81.
49. Bugge, T.H., Kombrinck, K.W., Xiao, Q., Holmba, ck.K.,Daugherty, C.C., Witte, D.P. and Degen, J.L. Growth and dissemination of Lewis lung carcinoma in plasminogen deficient mice. Blood 1997, 90(11): 4522-31.
50. Bugge, T.H., Lund, L.R., Kombrinck, K.K. et al. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998, 16(24): 3097-104.
51. Bajou, K., Noel, A., Gerard, R.D. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4(8): 923-8.
52. Gutierrez, L.S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V.A. and Castellino, F.J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000, 60: 5839-47.
53. Hudson, M.A. and McReynolds, L.M. Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 1997, 89(10): 709-17.
54. Plesner, T., Ralfkiaer, E., Wittrup, M. et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994, 102(6): 835-41.
55. Lanza, F., Castoldi, G.L., Castagnari, B. et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol 1998, 103(1): 110-23.
56. Liu, D., Ghiso, J.A., Estrada, Y. and Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1(5): 445-57.
57. Aguirre Ghiso, J.A., Kovalski, K. and Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999, 147(1): 89-104.
58. Whitley, B.R. and Church, F.C. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1. Int J Oncol 2005, 27(3): 749-57.
59. Wilson, A.J. and Gibson, P.R. Role of urokinase and its receptor in basal and stimulated colonic epithelial cell migration in vitro. Gut 2000, 47(1): 105-11.
60. Oh, S.H., Lee, O.H., Schroeder, C.P. et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006, 5(11): 2685-95.
61. Madsen, M.A., Deryugina, E.I., Niessen, S., Cravatt, B.F. and Quigley, J.P. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem 2006, 281(23): 15997-6005.
62. Merchan, J.R., Tang, J., Hu, G. et al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst 2006, 98(11): 756-64.
63. Mustjoki, S., Alitalo, R., Stephens, R.W. and Vaheri, A. Blast cell surface and plasma soluble urokinase receptor in acute leukemia patients: Relationship to classification and response to therapy. Thromb Haemost 1999, 81(5): 705-10.
64. Carriero, M.V., Del Vecchio, S., Franco, P. et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997, 3(8): 1299-308.
65. Morita, S., Sato, A., Hayakawa, H. et al. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization. Int J Cancer 1998, 78(3): 286-92.
66. Shetty, S. and Idell, S. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch BiochemBiophys 1998, 356(2): 265-79.
67. Hudson, M.A. and McReynolds, L.M. Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 1997, 89(10): 709-17.
68. Pyke, C., Kristensen, P., Ralfkiaer, E. et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991, 138(5): 1059-67.
69. De Petro, G., Tavian, D., Copeta, A., Portolani, N., Giulini, S.M. and Barlati, S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998, 58(10): 2234-9.
70. Taniguchi, T., Kakkar, A.K., Tuddenham, E.G., Williamson, R.C. and Lemoine, N.R. Enhanced expression of urokinase receptor induced through the tissue factor-factor Vila pathway in human pancreatic cancer. Cancer Res 1998, 58(19): 4461-7.
71. Yamamoto, M., Sawaya, R., Mohanam, S. et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994, 54(18): 5016-20.
72. Duffy, M.J. Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 2002, 30(2): 207-10.
73. Duffy, M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem 2002, 48(8): 1194-7.
74. Janicke, F., Prechtl, A., Thomssen, C. et al. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. German Chemotherapy Study Group. J Natl Cancer Inst 2001, 93(12): 913-20.
75. Look, M.P., van Putten, W.L.J., Duffy, M.J. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2000, 94(2): 116-28.
76. Duffy, M.J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J.J. and Lijnen, H.J. Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report. Cancer 1988, 62(3): 531-3.
77. Duffy, M.J., Duggan, C., Mulcahy, H.E., McDermott, E.W. and O'Higgins, N.J. Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998, 44(6 Pt. 1): 1177-83.
78. Duggan, C., Maguire, T., McDermott, E., O'Higgins, N., Fennelly, J.J. and Duffy, M.J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995, 61(5): 597-600.
79. De Bruin, P.A., Griffioen, G., Verspaget, H.W. et al. Plasminogen activators and tumor development in the human colon: Activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas: Cancer Res 1987, 47(17): 4654-7.
80. Skelly, M.M., Troy, A., Duffy, M.J. et al. Urokinase-type plasminogen activator in colorectal cancer: Relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997, 3(10): 1837-40.
81. Herszenyi, L., Plebani, M., Carraro, P. et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999, 86(7): 1135-42.
82. Harvey, S.R., Sait, S.N., Xu, Y. et al. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 1999, 155(4): 1115-20.
83. Wang, S.N., Miyauchi, M., Koshikawa, N. et al. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathol Int 1994, 44(12): 844-9.
84. Cantero, D., Friess, H., Deflorin, J. et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Thromb Haemost 1997, 77: 62-70.
85. Park, I.K., Kim, B.J., Goh, Y.J. et al. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int J Cancer 1997, 71(5): 867-73.
86. Ganesh, S., Sier, C.F., Heerding, M.M. et al. Urokinase receptor and colorectal cancer survival [letter]. Lancet 1994, 344(8919): 401-2.
87. Stephens, R.W., Nielsen, H.J., Christensen, I.J. et al. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999, 91(10): 869-74.
88. Suzuki, S., Hayashi, Y., Wang, Y. et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 1998, 43(6): 798-805.
89. Taniguchi, T., Lemoine, N.R. and Kakkar, A.K. Urokinase receptor is a key player in tumour progression. Gut 1998, 43(6): 739-40.
90. Sier, C.F., Verspaget, H.W., Griffioen, G. et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia: Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991, 101(6): 1522-8.
91. Sier, C.F., Vloedgraven, H.J., Ganesh, S. et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994, 107(5): 1449-56.
92. Bajou, K., Noel, A., Gerard, R.D. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4(8): 923-8.
93. Abe, J., Urano, T., Konno, H. et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999, 86(12): 2602-11.
94. Goodson, R.J, Doyle, M.V., Kaufman, S.E. and Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 1994, 91(15): 7129-33.
95. Schmidt, M. and Hoppe, F. Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients. Acta Otolaryngol 1999, 119(8): 949-53.
96. Pappot, H., Høyer-Hansen, G, Rønne, E. et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997, 33(6): 867-72.
97. Sier, C.F., Stephens, R., Bizik, J. et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998, 58(9): 1843-9.
98. Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S. and Kamidono, S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39(2): 123-9.
99. Fernebro, E., Madsen, R.R., Ferno, M. et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001, 37(4): 486-91.
100. Kobayashi, H., Gotoh, J., Fujie, M., Shinohara, H., Moniwa, N. and Terao, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1995, 57(5): 727-33.
101. Crowley, C.W., Cohen, R.L., Lucas, B.K., Liu, G., Shuman, M.A. and Levinson, A.D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A 1993, 90(11): 5021-5.
102. Lefesvre, P., Attema, J. and van Bekkum, D. Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. BMC Cancer 2002, 2: 17.
103. Kobayashi, H., Gotoh, J., Hirashima, Y., Fujie, M., Sugino, D. and Terao, T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumour cell invasion in vitro. J Biol Chem 1995, 270(14): 8361-6.
104. Kobayashi, H., Sugino, D., She, M.Y. et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumour cell invasion and metastasis. Eur J Biochem 1998, 253(3): 817-26.
105. Min, H.Y., Doyle, L.V., Vitt, C.R., Zandonella, C.L., Stratton-Thomas, J.R., Shuman, M.A. and Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumour growth in syngeneic mice. Cancer Res 1996, 56(10): 2428-33.
106. van der Pluijm, G., Sijmons, B., Vloedgraven, H. et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001, 159(3): 971-82.
107. Sidenius, N., Andolfo, A., Fesce, R. and Blasi, F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 2002, 277(31): 27982-90.
108. Dunn, S.E., Torres, J.V., Nihei, N. and Barrett, J.C. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy. Mol Carcinog 2000, 27(1): 10-7.
109. Zou, Z., Anisowicz, A., Hendrix, M.J. et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994, 263(5146): 526-9.
110. Cher, M.L., Biliran, H.R. Jr., Bhagat, S. et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A 2003, 100(13): 7847-52.
111. Yin, S., Lockett, J., Meng, Y. et al. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase- type plasminogen activator receptor system. Cancer Res 2006, 66(8): 4173-81.
112. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F. and Danø, K. The lig and-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991, 266(12): 7842-7.
113. Ploug, M., Kjalke, M, Rønne, E., Weidle, U., Høyer-Hansen, G. and Danø, K. Localization of the disulfide bonds in the NH2- terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchoredanchored membrane proteins. J Biol Chem 1993, 268(23): 17539-46.
114. Liu, S, Bugge, T.H. and Leppla, S.H. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001, 276(21): 17976-84.
115. Pulukuri, S.M., Gorantla, B. and Rao, J.S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator (uPA). J Biol Chem 2007, 282(49): 35594-603.
116. Pillay, V., Dass, C.R. and Choong, P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007, 25(1): 33-9.
117. Mohan, P.M., Chintala, S.K., Mohanam, S. et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 1999, 59(14): 3369-73.
118. Kin, Y., Chintala, S.K., Go, Y. et al. A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. Int J Oncol 2000, 17(1): 61-5.
119. Lakka, S.S., Rajagopal, R., Rajan, M.K. et al. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. Clin Cancer Res 2001, 7(4): 1087-93.
120. Wang, Y., Liang, X., Wu, S., Murrell, G.A. and Doe, W.F. Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 2001, 92(2): 257-62.
121. Haeckel, C., Krueger, S. and Roessner, A. Antisense inhibition of urokinase: Effect on malignancy in a human osteosarcoma cell line. Int J Cancer 1998, 77(1): 153-60.
122. Mohanam, S., Jasti, S.L., Kondraganti, S.R. et al. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res 2001, 7(8): 2519-26.
123. Gondi, C.S., Lakka, S.S., Yanamandra, N. et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003, 22(38): 5967-75.
124. Lakka, S.S., Gondi, C.S., Yanamandra, N. et al. Synergistic down-regulation of uroki nase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 2003, 63(10): 2454-61.
125. Rao, J.S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P.A. and Lakka, S.S. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 2005, 4(9): 1399-408.
126. Gondi, C.S., Lakka, S.S., Yanamandra, N. et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004, 64(12): 4069-77.
127. Wilhelm, O., Schmitt, M., Hohl, S., Senekowitsch, R. and Graeff, H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995, 13(4): 296-302.
128. Quattrone, A., Fibbi, G., Anichini, E. et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995, 55(1): 90-5.
129. Engelhard, H., Narang, C., Homer, R. and Duncan, H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 1996, 227(2): 400-5.
130. D'Alessio, S,, Margheri, F,, Pucci, M. et al. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 2004, 110(1): 125-33.
131. Margheri, F., D'Alessio, S., Serrati, S. et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005, 12(8): 702-14.
132. Nozaki, S., Endo, Y., Nakahara, H. et al. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 2005, 41(10): 971-97.
133. Tummalapalli, P., Gondi, C.S., Dinh, D.H., Gujrati, M. and Rao, J.S. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 2007, 31(1): 5-17.
134. Gondi, C.S., Lakka, S.S., Dinh, D.H., Olivero, W.C., Gujrati, M. and Rao, J.S. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007, 13(14): 4051-60.
135. Pulukuri, S.M., Gondi, C.S., Lakka, S.S. et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280(43): 36529-40.
136. Rockway, T.W., Nienaber, V. and Giranda, V.L. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 2002, 8(28): 2541-58.
137. Franco, P., Massa, O., Garcia-Rocha, M. et al. Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem 1998, 273(42): 27734-40.
138. Muehlenweg, B., Sperl, S., Magdolen, V., Schmitt, M. and Harbeck, N. Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumours. Expert Opin Biol Ther 2001, 1(4): 683-91.
139. Mackman, R.L., Hui, H.C., Breitenbucher, J.G. et al. 2-(2-Hydroxy-3- alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg Med Chem Lett 2002, 12(15): 2019-22.
140. Bridges, A.J., Lee, A., Schwartz, C.E., Towle, M.J. and Littlefield, B.A. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorg Med Chem 1993, 1(6): 403-10.
141. Barber, C.G., Dickinson, R.P. and Fish, P.V. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett 2004, 14(12): 3227-30.
142. Heynekamp, J.J., Hunsaker, L.A., Vander Jagt, T.A., Deck, L.M. and Vander Jagt, D.L. Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator. BMC Chem Biol 2006, 6: 1.
143. Setyono-Han, B., Sturzebecher, J., Schmalix, W.A. et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small syn thetic urokinase inhibitor WX-UK1. Thromb Haemost 2005, 93(4): 779-86.
144. Vassalli, J.D. and Belin, D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987, 214(1): 187-91.
145. Sperl, S., Jacob, U., Arroyo de Prada, N. et al. (4-Aminomethyl) phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc Natl Acad Sci U S A 2000, 97(10): 5113-8.
146. Ertongur, S., Lang, S., Mack, B. et al. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999, 9: 3147-52.
147. Schmalix, W. In vitro inhibition of invasion on HT 1080 fibrosarcoma cells and on MDA MB231 BAG human breast cancer cells through a fibrin gel. Wilex, Munich 2001.
148. Ertongur, S., Lang, S., Mack, B., Wosikowski, K., Muehlenweg, B. and Gires, O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004, 110(6): 815-24.
149. Wosikowski, K., Foekens, J., Setyono-Han, B., Stürzebecher, J., Tscheche, H. and Schmalix, W. Antimetastatic efficacy of WX-UK1 in a resected, spontaneously metastasizing rat mammary tumor model. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst. 788.
150. Wilex and Fox Chase Cancer Center begin clinical trial in the U.S. with novel compound WX-UK1 targeting tumor cell invasion and metastasis [news release]. Fox Chase Cancer Center; May 25, 2004. http://www.fccc.edu/news/ 2004/Wilex-Fox-Chase-05-25-04.html. Accessed February 15, 2008.
151. Killeen, S. D., Andrews, E.J., Wang, J.H. et al. Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor. WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases. Br J Cancer 2007, 96(2): 262-8.